|1.||Chen, Chen: 5 articles (06/2015 - 04/2010)|
|2.||Locatelli, V: 5 articles (07/2008 - 08/2000)|
|3.||Ghigo, E: 5 articles (03/2002 - 02/2000)|
|4.||Torsello, A: 4 articles (07/2008 - 12/2000)|
|5.||Ghigo, Ezio: 4 articles (05/2008 - 02/2002)|
|6.||Broglio, F: 4 articles (03/2002 - 02/2000)|
|7.||Deghenghi, R: 4 articles (04/2001 - 02/2000)|
|8.||Bresciani, Elena: 3 articles (11/2011 - 05/2003)|
|9.||Torsello, Antonio: 3 articles (11/2011 - 05/2003)|
|10.||Locatelli, Vittorio: 3 articles (11/2011 - 05/2003)|
06/01/2014 - "One dose of oral hexarelin protects chronic cardiac function after myocardial infarction."
02/01/1999 - "The GH secretagogue hexarelin improves cardiac function after experimental myocardial infarction either through an increased GH secretion or possibly through a cardiac GHS receptor, although this needs further investigation. "
06/01/2014 - "Although the mortality within 14 days after myocardial infarction did not differ between the groups, hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment. "
06/01/2014 - "The results first demonstrate that one dose of oral hexarelin treatment potentially protects chronic cardiac function after acute myocardial infarction, and implicate that activating growth hormone secretagogue receptor 1a might be beneficial for cardioprotection, although other mechanism may also be involved."
10/01/2013 - "This study aimed to clarify whether hexarelin treatment can compensate for ghrelin deficiency in ghrelin-knockout mice and to compare the effects of hexarelin (400 nmol/kg/d, sc) and equimolar ghrelin treatment after myocardial infarction. "
05/01/2008 - "Hexarelin, but not ghrelin, also showed a significant inhibition of apoptosis and necrosis. "
05/01/2008 - "Furthermore, hexarelin, but not ghrelin, showed protection against growth factor deprivation-induced apoptosis, as measured by annexin V binding and caspase-3 activity and also against necrosis, as measured by lactate dehydrogenase release. "
|3.||Heart Diseases (Heart Disease)
06/01/2015 - "Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases."
06/01/2015 - "Here, we review the physiological roles of ghrelin and hexarelin in the protection and regeneration of beta cells and their roles in the regulation of insulin release, glucose, and fat metabolism and present their potential therapeutic effects in the treatment of diabetes and diabetic-associated heart diseases. "
05/01/2003 - "We have previously reported that a 7-d pretreatment with hexarelin, a synthetic ligand of the GH secretagogue receptor (GHS-R), largely prevented damages induced by ischemia and reperfusion in isolated rat hearts. "
02/01/2001 - "These findings suggest that the inhibitory activity of hexarelin on cardiomyocytes and endothelial cell death could explain, at least partially, its cardioprotective effect against ischemia recorded in rats in vivo."
02/01/2001 - "Differently from nonpeptidyl GHSs, peptidyl molecules such as hexarelin, a hexapeptide, possess specific high-affinity binding sites in animal and human heart and, after prolonged treatment, protect rats in vivo from ischemia-induced myocardial damage. "
02/01/2000 - "In fact, hexarelin protects from ischemia-induced myocardial damage in aged and GH deficient rats while hexarelin shows a positive inotropic effect in normal subjects as well as in patients with GH deficiency. "
09/01/1999 - "In conclusion, we demonstrate that hexarelin prevents cardiac damage after ischemia-reperfusion, and that its action is not mediated by GH but likely occurs through activation of specific cardiac receptors."
|5.||Caspase 3 (Caspase-3)
|7.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|8.||Messenger RNA (mRNA)
|9.||Hydroxyproline (4 Hydroxyproline)